The Role of Prothrombin Complex Concentrates In the Treatment of Hemophiliacs with Factor VIII Inhibitors
- 1 December 1984
- journal article
- clinical trial
- Published by Wiley in Scandinavian Journal of Haematology
- Vol. 33 (S40) , 195-202
- https://doi.org/10.1111/j.1600-0609.1984.tb02564.x
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Hemophiliacs with Inhibitors: Therapeutic OptionsNew England Journal of Medicine, 1981
- The Effect of Activated Prothrombin-Complex Concentrate (FEIBA) on Joint and Muscle Bleeding in Patients with Hemophilia A and Antibodies to Factor VIIINew England Journal of Medicine, 1981
- NEW ACTIVATED FACTOR IX PRODUCT IN HAEMOPHILIAThe Lancet, 1980
- Anti-inhibitor Coagulant Complex (Autoplex) for treatment of factor VIII inhibitors in hemophiliaBlood, 1980
- Effects of Low-Dose ‘Factor VIII Inhibitor Bypassing Activity (FEIBA)’ in Resistant HaemophiliaActa Haematologica, 1980
- Activated F IX Concentrate (FEIBA) Used in the Treatment of Haemophilic Patients with Antibody to F VIIIActa Medica Scandinavica, 1978
- Factor VIII inhibitor by-passing activity (FEIBA) in the management of patients with factor VIII inhibitorsThrombosis Research, 1977
- FEIBA in haemophiliacs with factor VIII inhibitor.BMJ, 1977
- Prothrombin complex concentrate (Konyne) in the treatment of hemophilic patients with factor VIII inhibitorsThe Journal of Pediatrics, 1976